Sarepta Therapeutics | SRPT - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amgen USD 95.64B 94.98B 2026-06
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Capricor Therapeutics 3.05M 2.46M 2025-12
Daiichi Sankyo JPY 3.57B 1.4B 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 247M 7M 2026-06
Incyte USD 582K 13K 2026-06
Insmed USD 18.84M 1.24M 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Novavax USD 5.82M 342K 2025-12
Pfizer USD 667M 4M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 287M 109M 2026-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Tectonic Therapeutic USD 246.58M 246.56M 2026-03
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12